Tumor Mutations and anti-PD-1 Immunotherapy Response - Hallo friendsLET'S HEALTHY LIFE, In the article you read this time with the title Tumor Mutations and anti-PD-1 Immunotherapy Response, We have prepared this article for you to read and retrieve information therein. Hopefully the contents of postings Article cough, Article diabetes, Article diseases, Article in general, Article Phytotherapy, Article skin diseases, We write this you can understand. Alright, good read.

Title : Tumor Mutations and anti-PD-1 Immunotherapy Response
link : Tumor Mutations and anti-PD-1 Immunotherapy Response

Tumor Mutations and anti-PD-1 Immunotherapy Response

Inhibitors of factors that themselves inhibit an anti-tumor response are promising therapeutic agents.  Here we see once again that response to such agents is related to the number of mutations a tumor has.  The more mutations, the more neoantigens produced – the more aberrant proteins produced that can be recognized by the immune system once the “brakes” are off.  Excerpts (figure shown is from the paper, which is freely accessible online):

Inhibitors of programmed death 1 (PD-1) protein or its ligand (PD-L1) have shown remarkable clinical benefit in many cancers. One emerging biomarker of response to anti–PD-1 therapy is the tumor mutational burden (i.e., the total number of mutations per coding area of a tumor genome). This finding is supported by the clinical activity of anti–PD-1 therapy in colorectal cancer with mismatch repair deficiency, a tumor subtype with a high tumor mutational burden, as compared with the colorectal cancer subtype with mismatch repair proficiency, which has a significantly lower tumor mutational burden and a poor response to these agents. 

To evaluate the relationship between the tumor mutational burden and the objective response rate, we plotted the objective response rate for anti–PD-1 or anti–PD-L1 therapy against the corresponding median tumor mutational burden across multiple cancer…We observed a significant correlation between the tumor mutational burden and the objective response rate (P<0.001). The correlation coefficient of 0.74 suggests that 55% of the differences in the objective response rate across cancer types may be explained by the tumor mutational burden. 

Thus Article Tumor Mutations and anti-PD-1 Immunotherapy Response

That's an article Tumor Mutations and anti-PD-1 Immunotherapy Response This time, hopefully can give benefits to all of you. well, see you in posting other articles.

You are now reading the article Tumor Mutations and anti-PD-1 Immunotherapy Response with the link address https://letslifes.blogspot.com/2018/01/tumor-mutations-and-anti-pd-1.html

Tweet

Subscribe to receive free email updates: